Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive…
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its…
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity…
Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its…
CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring…
FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease,…
Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO…
Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for…
Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal…
Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies,…
Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals, a global leader in RNA interference…